Advertisement

 

 

Removal from liver transplantation list of an hepatitis C virus-HIV co-infected patient after successful treatment with sofosbuvir and daclatasvir.

Author Information (click to view)

Llaneras J, Castells L, Santos B, Crespo M, Puig T, Esteban JI, Esteban R,


Llaneras J, Castells L, Santos B, Crespo M, Puig T, Esteban JI, Esteban R, (click to view)

Llaneras J, Castells L, Santos B, Crespo M, Puig T, Esteban JI, Esteban R,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Transplant infectious disease : an official journal of the Transplantation Society 2016 4 2() doi 10.1111/tid.12538

Abstract

We present an human immunodeficiency virus-infected patient with severe decompensated hepatitis C virus-related cirrhosis awaiting liver transplantation (LT) who received a 24-week course of interferon/ribavirin-free antiviral treatment with sofosbuvir and daclatasvir on a compassionate basis. Rapid viral suppression was associated with progressive improvement of his liver function tests. The patient achieved a sustained virological response and concomitant clinical improvement, which prompted removal from the LT list 12 weeks after the end of treatment. This article is protected by copyright. All rights reserved.

Submit a Comment

Your email address will not be published. Required fields are marked *

3 × 5 =

[ HIDE/SHOW ]